|

Iparomlimab and Tuvonralimab (QL1706) Clinical Trials

4 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 4

Top Sponsors

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
  • Sun Yat-sen University1
  • Shanghai Zhongshan Hospital1
  • Beijing Friendship Hospital1

Indications

  • Cancer4
  • Liver Disease1
  • Biliary Tract Cancer (BTC)1
  • Advanced Gastric Cancer1
  • Metastatic Gastric Cancer1

Other4 trials

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Phase 2
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Phase 2
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Phase 2
QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.